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ABSTRACT  
Type 1 diabetes and celiac disease result from misdirected immune mediated destruction of host cells, and 
are among the most common chronic diseases in children. Despite changes in incidence over the past 3 de-
cades, little is known about non-genetic risk factors (except for dietary gluten for celiac disease). Norway 
is among the countries in the world with the highest incidence of these two diseases. We describe here 
plans and study design for the PAGE study (Prediction of Autoimmune diabetes and celiac disease in 
childhood by Genes and perinatal Environment). PAGE is a sub-study within the Norwegian Mother and 
Child Cohort study, including follow-up of more than 100,000 pregnancies. Children who develop type 1 
diabetes or celiac disease are identified via linkage to the Norwegian Patient Register and the Norwegian 
Childhood Diabetes Registry, with complementing information from questionnaires. The overall aim is to 
test hypotheses about potential non-genetic risk factors for type 1 diabetes and for celiac disease, with focus 
on factors operating early in life. In addition to a full cohort analysis of factors registered in questionnaires, 
we will analyse biomarkers in maternal blood plasma and cord blood plasma. Mothers and children will be 
genotyped for well-established susceptibility polymorphisms. Biomarkers will be analysed in cases and 
controls within the cohort. Factors to be tested in the full cohort include infant feeding, diet and dietary 
supplements in the mother during pregnancy and in the child, and use of antibiotics and non-prescription 
drugs. Biomarkers to be tested include 25-hydroxyvitamin D, markers of immune activation, and small 
metabolites (metabolomics). We will also explore the potential role of maternal cells in the fetal circulation 
(maternal microchimerism) in later risk of celiac disease and type 1 diabetes. 
 
This is an open access article distributed under the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
 
 
INTRODUCTION 
 
Type 1 diabetes and celiac disease are among the most 
common chronic diseases with onset in childhood. 
Type 1 diabetes is due to an autoimmune selective 
destruction of the insulin producing beta-cells in the 
pancreas (1), leading to excessive blood sugar unless 
treated with exogenous insulin injections. As optimal 
therapy is difficult to achieve, many patients suffer 
acute complications such as hypoglycaemia and diabe-
tic ketoacidosis, and late complications in the eyes, 
kidneys, peripheral nerves and cardiovascular diseases. 
Together with Finland and Sweden, Norway is among 
the countries in the world with the highest incidence of 
type 1 diabetes in children (2,3). 
 Celiac disease results from a misdirected, cell medi-
ated immune response to dietary gluten that leads to 
inflammation and flattening of the gut mucosa with 
resulting malabsorption and long-term complications 
such as osteoporosis and gastrointestinal cancers (4). 
The current treatment is limited to a lifelong gluten-
free diet. Both celiac disease and type 1 diabetes are 
associated with reduced quality of life and life 
expectancy (5,6). Along with Sweden, Norway has a 
very high incidence of diagnosed celiac disease among 
children, compared to other countries (7). 
 The two diseases have a number of interesting fea-
tures in common, and tend to occur together (8). The 
majority of celiac disease and type 1 diabetes patients 
carry the HLA-DQ2 haplotype and/or the DQ8 haplo-
type (9,10). As these haplotypes are relatively common 
in the population and the minority of those with one or 
even two risk haplotypes develop disease, HLA sus-
ceptibility alleles seem necessary but not sufficient for 
disease. Additional causal factors are therefore likely 
involved. Circulating autoantibodies may be predictive 
of clinical disease months and years before onset of 
both diseases (1,4,11). The fact that these may appear 
before six months of age and frequently appear before 
two to three years of age (12,13) suggest that factors 
influencing the seroconversion operate early in life. 
 Here, we describe the study design and the initial 
research questions in the PAGE-study: Prediction of 
Autoimmune diabetes and celiac disease in childhood 
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by Genes and perinatal Environment. While insulin 
replacement and gluten-free diet are established treat-
ments for type 1 diabetes and celiac disease, respec-
tively, there is currently no cure for either disease, and 
no established intervention to reduce the risk of disease 
by pharmacological intervention or otherwise. 
 The overall goal of the study is to increase our un-
derstanding of the aetiology of these diseases, particu-
larly how specific environmental factors in early life, 
including in utero, can predict risk of autoimmune type 
1 diabetes and celiac disease in childhood. Potential 
positive findings could be informative for planning of 
future preventive trials. Another important rationale 
for the study is that even “negative results” (lack of 
associations) would be informative for patients and 
families who could then lay to rest worries about 
potential “self-inflicted” causes of these diseases. 
 In the next paragraphs, we first provide a brief in-
troduction to what we already know about genetic and 
non-genetic factors in the aetiology of celiac disease 
and type 1 diabetes (focusing primarily on biomark-
ers), before we describe the specific aims of the study, 
and then describe the methods. We finish off with a 
brief glance into the future. 
 
GENETIC FACTORS AND GENE-
ENVIRONMENT INTERACTIONS 
 
An important role of HLA genetics in both diseases is 
well established. Nevertheless, only a minority of those 
with HLA susceptibility genes develop disease. A large 
number of non-HLA SNPs have also been identified in 
both diseases (4,14,15). Non-HLA SNPs generally con-
fer weak associations, and even when combined, they 
have limited predictive power compared with that of 
HLA genes (16,17). Together with evidence discussed 
below, this suggests that environmental factors are also 
involved in both diseases. In fact most diseases and 
traits are likely a result of both genetic and non-genetic 
factors (18). The PAGE study will not attempt to iden-
tify novel susceptibility genes, as this is better done in 
large genetics consortia. Rather, the strength in PAGE 
is the ability to study non-genetic factors with a pros-
pective collection of blood and questionnaires. Pros-
pective cohort studies offer unique advantages for the 
study of gene-environment interactions, as retrospec-
tive assessment of exposure to non-genetic factors are 
fraught with measurement error and potential bias 
(19). Because of the considerable resources required, 
there are few large scale, population based prospective 
studies of non-genetic factors risk factors for type 1 
diabetes or celiac disease. 
 
EARLY ENVIRONMENTAL FACTORS IN 
CELIAC DISEASE AND TYPE 1 DIABETES 
 
While there are many hypotheses and abundant cir-
cumstantial evidence, no aetiological environmental 
factor has yet been convincingly identified in type 1 
diabetes (20-22). In celiac disease, dietary intake of 
gluten is necessary for expression of the disease, but 
this is not a sufficient cause. Limited efforts have so 
far been invested in the search for other non-genetic 
factors in celiac disease. 
 The incidence of both diseases varies between 
countries, even within Europe, and has increased over 
time (2,23). During 2000-2010, the incidence rate of 
clinically detected cases of celiac disease in children in 
South-Eastern Norway has increased from 16 to 
44/100.000/person-years (K. Størdal et al., unpublished 
observation). Sweden has experienced an epidemic 
with cohort effects on cumulative incidence (24). Such 
rapid changes cannot be explained by changes in the 
genetic composition of the population. 
 The autoimmune process leading to celiac disease 
and type 1 diabetes occurs early in life. Islet autoanti-
bodies may appear before 6 months, often in the first 
1-4 years of life (12,13), and tissue transglutaminase 
autoantibodies somewhat later (11,25). Perinatal factors 
such as birth weight and caesarean section have been 
associated with both type 1 diabetes and celiac disease 
(26-28). These factors are likely markers of other, yet 
unknown processes. We must therefore focus on 
factors operating very early in life, even in utero, to 
understand how autoimmunity initiates (21). 
 
 
NUTRITIONAL FACTORS AND METABOLITES 
 
Breast feeding and introduction of cereals 
There is circumstantial evidence for a role of breast-
feeding and timing of introduction of cereals in both 
type 1 diabetes and celiac disease, mostly based on 
retrospective studies (29,30). It is likely that potential 
relationships here may be very complex, and involving 
potentially numerous different mechanisms such as 
development and integrity of the infant gut, exposure 
to foreign antigens, gut microbiota, and protection 
against infections. A few prospective studies of selec-
ted children at increased genetic risk have generally 
not found any consistent associations with islet auto-
immunity or type 1 diabetes (31,32), while studies of 
celiac disease have indicated potential increased risk 
with late introduction of gluten (33,34). Two recent 
randomised trials have investigated the effect of timing 
of introduction of gluten on risk of celiac disease, and 
they found no discernible effect (35,36). One random-
ised trial tested whether delaying the introduction of 
intact cow’s milk in genetically susceptible infants 
would reduce the risk of islet autoimmunity, but found 
no significant effect (37). In all three trials, partici-
pants were encouraged to breastfeed, and duration of 
breastfeeding was not associated with endpoint in 
observational analyses in any of the trials. 
 
Plasma metabolome profiling 
The plasma metabolome and -lipidome refer to the 
collection of small metabolites, and lipids, respec-
tively, in blood plasma. With limited knowledge of the 
nature of potential factors predictive of type 1 diabetes 
and celiac disease, it makes sense to explore potential 
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biomarkers using an “omics” approach by comparing 
children who later develop disease with controls. The 
actual metabolites that are reliably detected depend on 
sample handling and quality as well as the available 
technology for profiling the sample. Metabolomics 
platforms are usually categorised into targeted or non-
targeted, but a variety of factors influence the detect-
able analytes. In practice, the available technology we 
aim to use detects up to a few hundred, small, hydro-
philic (water soluble) metabolites. The Finnish DIPP 
study reported patterns in the serum or plasma lipidome 
and metabolome associated with islet autoimmunity, 
some of which persisted from birth (38). For instance, 
the appearance of diabetes associated autoantibodies 
(markers of “prediabetes”) was preceded by lower 
serum levels of ketoleucine and elevated glutamic acid 
in this study. We are not aware of any such studies in 
celiac disease. The plasma lipidome is very sensitive 
to sample handling conditions, and we may have to 
limit or exclude lipidomics from PAGE for this reason, 
while we aim to include metabolomics. 
 
Vitamin D 
Vitamin D status, measured by serum or plasma 25-
hydroxyvitamin D, is influenced by both dietary vita-
min D and synthesis in the skin upon ultra violet light 
exposure. Many studies on type 1 diabetes are based 
on maternal recall of their children’s use of supple-
ments, while the few prospective studies have limited 
numbers with clinical endpoint (39). Published studies 
of 25-hydroxyvitamin D in childhood (40) or maternal 
samples from pregnancy (41,42) are very few, and 
have shown mixed results. The apparent inconsistent 
results may be due to methodological factors and tim-
ing of samples. Intake of vitamin D is likely to change 
during pregnancy, in addition to changes in physiology 
of metabolites in the vitamin D “pathway”. We have 
preliminary data from another cohort (41,43) suggest-
ing also an association between vitamin D binding 
protein (DBP) in pregnancy and type 1 diabetes in the 
offspring. DBP probably has multiple physiological 
effects apart from acting as a carrier from 25-
hydroxyvitamin D and other vitamin D metabolites, 
and DBP is also known to increase during pregnancy 
(44,45). If associations with 25-hydroxyvitamin D in 
late pregnancy and type 1 diabetes (and perhaps also 
with celiac disease) can be confirmed, it would 
provide a basis for planning future intervention studies 
with vitamin D supplements to pregnant women. We 
are not aware of studies of vitamin D in relation to risk 
of celiac disease, but we aim to study this for the first 
time in PAGE. 
 
 
MARKERS OF IMMUNE ACTIVATION AND 
INFLAMMATION 
 
Inflammation probably plays an important, but comp-
lex role in a large number of diseases of public health 
importance including celiac disease and type 1 diabetes 
(1,46). We will focus on a limited selection of soluble 
markers of immune activation or inflammation in the 
perinatal period. Various studies have implicated cyto-
kines such as interleukin (IL) 1β, interferon gamma 
(IFN-γ), IL-2, and the chemokines CXCL10 (IP10) 
and MCP-1 (CCL2) in type 1 diabetes, celiac disease, 
or related disorders. Pregnancy levels of these in rela-
tion to disease in the offspring have been investigated 
in a few moderately sized studies (47,48). 
 Neopterin is a recently “rediscovered” biomarker, 
which is considered a relatively stable marker of cellu-
lar immune activation. It is produced by macrophages 
under the influence of interferon-gamma (49), which is 
characteristic of Th-1 immune responses. In fact, and 
early study found that urinary neopterin seemed to be 
increased in celiac disease, but little more came out of 
this story (50). Neopterin may change during preg-
nancy, and has been associated with for instance pre-
eclampsia (51). Another marker we plan to measure is 
the kynurenine:tryptophan ratio (52). This is also a 
marker of T-helper 1 immune activation, considered 
more stable during sample handling than cytokines 
(53). 
 
MATERNAL MICROCHIMERISM 
 
An understudied area that may play a role is maternal 
microchimerism (54). The engraftment of maternal 
cells in the foetus, known as maternal microchimerism 
(MMc), was initially recognized in children with 
severe combined immunodeficiency. Maternal cells 
were identified in umbilical cord blood samples from 
healthy male infants in 1995 (55). The placenta is 
therefore not an impenetrable barrier to cellular traffic 
and it has been shown that MMc can persist for many 
years in healthy individuals (56). This suggests the 
maintenance of immune tolerance to genetically 
distinct maternal cells in health. The mechanism 
underlying this naturally obtained tolerance is 
unknown. It has recently been shown that substantial 
numbers of maternal cells cross the placenta to reside 
in fetal lymph nodes inducing development of 
CD4+CD25highFoxP3+Tregs that suppress fetal anti-
maternal immunity and persist for many years (57). 
One might therefore hypothesise that increased levels 
of MMc that has been reported in the periphery in 
several forms of autoimmunity including type 1 dia-
betes (58) may indicate a failure in anti-maternal 
tolerance. We are not aware of such studies in celiac 
disease, and no study of cord blood MMc and type 1 
diabetes has to our knowledge been done yet. 
 
SPECIFIC AIMS OF THE PAGE STUDY 
 
Specific aims for biomarker studies 
The specific objectives of the current project are to test 
whether the below listed factors, together with estab-
lished susceptibility genes, can predict risk of type 1 
diabetes and celiac disease (these will also be tested 
for gene-environment interactions): 
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• Lower levels of 25-hydroxvitamin D in cord blood 
or maternal blood near delivery (We will also mea-
sure vitamin D binding protein, and genetic markers 
such as Gc/DBP and CYP27B1 in addition to HLA 
genotype as part of this sub-project. Vitamin D 
metabolites will be measured in maternal sample 
from mid pregnancy and at delivery as well as in 
cord blood, and we will also investigate changes 
during pregnancy and relation between maternal and 
fetal levels in relation to disease outcome). 
• Pattern identified by metabolomics profiling of cord 
vein plasma (lipidomics profiling will be considered, 
depending on the quality of the specimens). 
• Maternal markers of immune activation or in-
flammation, including selected cytokines mentioned 
above, C-reactive protein, neopterin and the 
kynurenine:tryptophan ratio. 
• Estimated quantity of maternal cells in the fetal cir-
culation, as determined by the quantity of maternal 
DNA. (see methods for more details. While the 
exact role and mechanism of the increased levels of 
maternal microchimerism observed in previous stu-
dies is not known, the novel research question in the 
PAGE study is whether an increased level of mater-
nal cells in the child’s circulation can be observed 
already at birth, as measured in cord blood). 
 
Specific aims for questionnaire based studies:  
• Specific factors prospectively collected in question-
naires will be tested for statistical association with 
higher or lower risk for type 1 diabetes and celiac 
disease (these will also be tested for gene-environ-
ment interaction): 
• Short duration of breastfeeding, early introduction 
of gluten and other solid foods during weaning, use 
of dietary supplements and cod liver oil by the mot-
her during pregnancy and by the child in the first 
three years of life. 
• Maternal body mass index and weight gain during 
pregnancy. 
• Child’s postnatal growth in body height, weight and 
body mass index. 
• Maternal smoking during pregnancy (the hypothe-
sis, based on limited previous studies (21,59), is that 
children whose mother smoked during pregnancy 
had lower risk of type 1 diabetes. For celiac disease, 
the literature is inconclusive). 
• Use of non-prescription anti-inflammatory medica-
tions by the mother during pregnancy and by the 
child in the first years of life. 
• Use of antimicrobial medication (antibiotics) by the 
mother during pregnancy and by the child in the 
first three years of life (reported in questionnaires; 
unpublished pilot results based on Register linkage 
were suggestive of a relation between early or re-
peated use of antibiotics and risk of type 1 diabetes 
(60) and preliminary data also suggest a relation for 
celiac disease (Størdal & Stene, abstract at the 
ESPGHAN meeting, 2014). 
• Reported diseases and symptoms during the child’s 
first three years of life, including gastrointestinal in-
fections and respiratory tract infections. 
• Asthma, eczema and allergies in the children (the 
literature on this topic is inconsistent, but early 
childhood eczema has frequently been found to be 
associated with lower risk of type 1 diabetes, pri-
marily in retrospective studies (61)).  
• Maternal education and other socioeconomic indica-
tors: The scattered literature is inconsistent, but our 
hypothesis is based on a suggestive association 
between high maternal education and lower risk of 
type 1 diabetes (6). Describing the potential associa-
tion of socioeconomic status with both celiac disease 
and type 1 diabetes, or lack thereof, is important in 
order to learn more about the nature of the elusive 
environmental triggers.  
 
 
METHODS 
	  
Study design 
The PAGE study is based on biobanked plasma and 
DNA samples and questionnaire data collected from 
over 100.000 pregnancies in the Norwegian Mother 
and Child Cohort study (MoBa, (62,63)). Cases with 
type 1 diabetes will be identified by register linkage to 
the Norwegian Childhood Diabetes Registry, which 
stores blood from diagnosis as well as detailed data on 
clinical characteristics (3,64), as well as the Norwegian 
Patient Registry (NPR) (7). The NCDR is based on 
consent from the participants and/or the parents/guar-
dians (www.barnediabetes.no). By register linkage to 
NorPD (prescription drug register, using insulin 
purchase as indicator of type 1 diabetes diagnosis), we 
estimated that the ascertainment for children diagnosed 
before 15 years of age during 2004-2008 was 91% (3). 
A few cases of type 1 diabetes may therefore be 
missed, of whom some may be captured in the Norwe-
gian Patient Register. As long as the ascertainment is 
>90%, we consider it most important for validity that 
the captured cases are true type 1 diabetes cases. To 
miss a few true cases is less important that to include 
false cases (non-diabetes, or other forms of diabetes 
such as monogenic forms, type 2 diabetes). Celiac dis-
ease will be identified from a combination of NPR and 
standard MoBa questionnaires. A minimum of two 
entries with celiac disease (K90.0) in the NPR is used 
as a criterion, to avoid false positives given the diagno-
sis during a diagnostic process. Questionnaires have 
been sent to the potential cases identified from NPR 
and questionnaires to confirm the diagnosis, indicating 
that 95% of the identified cases are true celiac cases. 
Additionally, information regarding the diagnosis and 
symptoms in cases has been collected. 
 A set of controls randomly selected from the whole 
MoBa-cohort will be used in common for both disea-
ses. The established genetic markers will be investiga-
ted together with other biomarkers and questionnaire 
data, including gene-environment interaction analyses. 
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Figure 1.  Overview of concept and design of the PAGE study. In the Norwegian Mother and Child Cohort Study, over 
108 000 pregnancies are followed prospectively. Blood samples are available from the mother at 17-20 gestational weeks 
and at delivery, and from the umbilical vein, representing the fetal circulation. Information regarding demographic factors, 
diet, lifestyle and relevant environmental exposures are collected twice during pregnancy and when the child is 6, 18 and 36 
months, indicated by Q in the figure. Type 1 diabetes (T1D) is ascertained by linkage to the Norwegian Childhood Diabetes 
Registry (www.barnediabetes.no), which also stores blood collected at diagnosis. Celiac disease will be ascertained pri-
marily by linkage to the Norwegian Patient Registry, but also by supplemental information from questionnaires. 
 
 
Figure 1 outlines the concept and design of the PAGE 
study. 
 MoBa questionnaires with information on diet, 
lifestyle, medication, socio-economic status and other 
environmental factors we propose to utilize are collec-
ted at gestational week 15, 22, and at birth, and when 
the child is 6,18 and 36 months. The prospective 
collection of information during pregnancy minimises 
the risk for recall bias, a problem in most other studies. 
The Norwegian Patient Registry (NPR) has collected 
information on diagnoses in the health care system 
with data traceable to individuals since 2008. Celiac 
disease has to be diagnosed by a paediatrician or a 
gastroenterologist in Norway. We also include specific 
questionnaires to celiac disease cases identified in 
NPR, to obtain confirmative information about the 
diagnosis and additional information about the timing 
and nature of initial symptoms. 
 For type 1 diabetes, clinical characteristics, inclu-
ding family history, islet autoantibodies, and screening 
results for celiac disease are routinely collected at 
diagnosis and thereafter in the Norwegian Childhood 
Diabetes Registry. Phenotypic classification is based 
on clinical and genetic information, including HLA 
genotype, and suspected cases of monogenetic forms 
of diabetes are screened. 
 
Vitamin D metabolite assays 
Plasma 25-hydroxyvitamin D will be assayed using 
liquid chromatography followed by tandem mass spec-
trometry (LC-MS/MS). Vitamin D binding protein 
(DPB) and 1,25-dihydroxyvitamin D both will be mea-
sured using commercial radioimmunoassays (RIA). 
(Genotyping of SNPs in the DBP/GC gene and the 
CYP27B1 gene will be done as described under geno-
typing below). 
 
Metabolomics and lipidomics profiling 
Cord vein plasma and maternal plasma from pregnan-
cy will be subjected to metabolomics profiling using 
ultra-high pressure liquid chromatography (UPLC) 
combined with mass spectrometry (MS), and by gas 
chromatography - time of flight mass spectrometry 
(GCxGC-TOF/MS) (38). 
 
Markers of inflammation 
A limited number of selected cytokines and chemo-
kines of particular interest, including IL-1β, IFN-γ, IL-
2, CXCL10 (IP10) and MCP-1 (CCL2) and C-reactive 
protein, will be measured in maternal mid-pregnancy 
venous blood plasma Luminex technology. Neopterin, 
kynurenine and tryptophan will be measured using 
liquid chromatography/tandem mass spectrometry 
(LC-MS/MS) (65). 
 
Maternal microchimerism assays 
DNA has been isolated from cord blood in MoBa, and 
the Norwegian Childhood Diabetes Registry have 
stored DNA isolated from venous blood drawn at diag-
nosis from type 1 diabetes cases. The non-inherited 
HLA allele will be determined from the HLA genotype 
of the mother and child. Quantitative PCR (qPCR) 
specific for the un-transmitted HLA allele will be 
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carried out as described (58). Briefly, the method 
quantifies DNA originating from maternal cells, and is 
expressed as genomic equivalents (an estimate of 
number of maternal cells). 
 
Genotyping 
For the purpose of the study, we will use tagSNPs to 
determine HLA genotypes of relevance to risk of type 
1 diabetes and celiac disease, and for non-inherited 
maternal alleles. This is an alternative to labour (and 
cost) intensive traditional HLA genotyping with a 
large number of allele-specific primers and/or probes. 
This will imply a certain loss of accuracy of the geno-
typing, which is acceptable for most aspects of the 
study. For the maternal microchimerism analyses, the 
maternal HLA allele predicted from the SNP typing 
will be sought confirmed with traditional, in house 
allele specific PCR primer set assays. We will also 
genotype currently established non-HLA susceptibility 
loci for type 1 diabetes and coeliac disease (approxi-
mately 150 non-HLA SNPs (14,15)) using an Illumina 
Golden Gate custom chip. 
 
Data analysis 
Analysis will primarily be based on logistic and linear 
regression models. Continuous variables will be tested 
primarily by tests for trend, and dose response effects 
evaluated using categorisation and smoothing splines. 
Interactions will be tested by adding interaction terms 
to the models. qPCR data from the maternal micro-
chimerism part of the project will be analysed using 
linear regression models applied to ranks of the MMc 
values. Metabolomics data will be adjusted for 
multiple tests using the (FDR-related) q-value (66). 
For each type predictor investigated, analyses will be 
adjusted for and stratified by markers of genetic 
susceptibility. 
 
Sample size 
Based on external incidence data for celiac disease and 
type 1 diabetes and known proportions of missing 
blood samples and questionnaires, we projected that 
around 200 cases with type 1 diabetes and more than 
400 cases of celiac disease would be available for 
analysis in MoBa by 2013. This has now (Aug 2014) 
been confirmed. Since many of the assays are rela-
tively expensive, we decided based on a cost vs power 
trade off to include 600 controls (3:1 for diabetes and 
1.5:1 for celiac disease). In 2013, the PAGE study was 
funded by the Research Council of Norway to carry 
out these planned analyses. We project that by the time 
all MoBa-children has turned 15 years old, nearly 500 
cases of type 1 diabetes will have been diagnosed, and 
a much larger number will have been diagnosed with 
celiac disease. 
 
Statistical power considerations 
The approximately 200 type 1 diabetes cases and 600 
common controls will provide between 81 and 99% 
power to detect significant differences at the 5% level, 
for dichotomous exposure variables with between 10 
and 80% prevalence, as long as the true odds ratio for 
association is 2.0, and higher power if the true odds 
ratio is higher (and higher power for celiac disease, for 
which there are 400 cases). For maternal plasma 25-
hydroxy-vitamin D, we have published a significant 
(logit-) linear association with type 1 diabetes with 109 
cases and 219 controls in an independent study cohort 
(41). The mean was 66nM and 73nM in cases and con-
trols, respectively, and the standard deviation 27nM in 
both groups. With 200 cases and 600 controls, we will 
have 91% power to detect a similar difference in mean 
between cases and controls in the currently proposed 
study. Some aspects of the project are novel, and the 
magnitude of potential differences impossible to pro-
ject, with resulting uncertainties in power calculations. 
 
COLLABORATIONS WITH OTHER COHORTS 
 
Experience from genetic epidemiology has shown that 
replication is the most reliable way of protecting 
against chance findings (false positive findings). Due 
to the relatively low percentage of children from the 
general population who develops celiac disease or type 
1 diabetes, prospective studies must be very large with 
years of follow-up for a large number of endpoints to 
accrue. For this reasons, there are very few cohorts 
available. Depending on the nature of the findings in 
PAGE, some results can probably be sought replicated 
in one of the existing cohorts with genetically suscepti-
ble children such as MIDIA, http://www.fhi.no/MIDIA 
(12) and other similar cohorts (67). However, we must 
keep in mind that these studies differ from PAGE in 
many aspects of design and target group. 
 The only other study we are aware of that is directly 
comparable to MoBa and PAGE, is MoBa’s Danish 
“sister cohort”, the Danish National Birth Cohort (68). 
We have specific plans with Danish collaborators to 
coordinate analyses of several potential risk factors for 
both type 1 diabetes and celiac disease. The Danish 
cohort is of comparable size and will contribute a com-
parable number of cases with type 1 diabetes, but a 
smaller number of celiac disease cases, because of the 
enigmatic lower incidence of celiac disease in Denmark 
compared with Norway. Jointly, the two cohorts will 
amount to the largest population-based birth cohort of 
celiac disease and type diabetes in the world. 
 
CONCLUDING REMARKS 
 
With increasingly long follow-up time, more cases will 
accrue with consequent increase in total statistical 
power, and the potential to replicate initial findings 
using future cases developing the cohort. It is perfectly 
possible that the truly causative non-genetic risk fac-
tors we are searching for are not on the list of current 
hypotheses, but the biobanks make it possible to test 
novel factors in the future and thus has tremendous 
value. Depending on funding, a number of additional 
biomarkers could be tested. However, we must always 
1 
cell  
5 
cell
s 
10 
cells 
500 
cells … 
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consider the trade-off between testing current hypothe-
ses and saving material for the future to replicate novel 
hypotheses. PAGE has its strength in the wealth of 
data from pregnancy and early postnatal life, and the 
large sample size, but lacks detailed follow-up data 
and longitudinally collected biological material in 
studies such as MIDIA and other high risk cohorts 
mentioned above. Together with the handful of other 
prospective studies in the field, we feel confident that 
the PAGE study will contribute to fulfil our ultimate 
goals to enhance the understanding of the aetiology of 
celiac disease and type 1 diabetes, and one day, hope-
fully, an intervention to reduce the incidence of these 
diseases.  
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